Literature DB >> 8684005

Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.

J V Melo1, X H Yan, J Diamond, F Lin, N C Cross, J M Goldman.   

Abstract

Technical modifications of the reverse-transcription/polymerase chain reaction (RT/PCR) amplification method now permit its use to detect amplified products from as few as one abnormal cell, either isolated or mixed with a larger number of normal cells. We studied the reproducibility of such results using as targets low numbers of cells from chronic myeloid leukaemia (CML) patients and CML cell lines in quintuplicate two-step RT/PCR designed to amplify BCR-ABL sequences. When one K562 or KYO1 cell was diluted in 10(3) non-CML HL60 cells, an amplification product was obtained in each test; at greater dilutions BCR-ABL transcripts were detected erratically. Titration of cDNA synthesised from 5 x 10(7) cells from four CML patients showed that whereas positive BCR-ABL sequences could be amplified in some tests starting with as little as a 1 in 10(7) dilution of cDNA template (corresponding to 5-10 cells), the dilution threshold for reproducible amplification was around 1 to 5 in 10(5) (100-500 cells). Quantitative PCR analysis revealed that reactions from 1 in 10(7) diluted cDNA contained less than 10 BCR-ABL transcripts as the starting template. The stochastic nature of the amplification from such small numbers of transcripts was illustrated by results of 10 replicate PCR tests on cDNA from a patient expressing both b3a2 and b2a2 transcripts: dilutions of cDNA up to 1 in 10(5) yielded dual transcript amplification in all 10 tests, but the 1 in 10(7) cDNA dilution resulted in b3a2 and b2a2 products in three tests, b3a2 only in three, b2a2 only in one and no amplification in three tests. We conclude that this 'sampling effect' may yield false-negative results and thus misinterpretation of data regarding assessment of gene expression when the quantity of target material available for study is very small.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8684005

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era.

Authors:  Haiyan He; Yang Shen; Yongmei Zhu; Saijuan Chen
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

2.  Plectin rodless isoform expression and its detection in mouse brain.

Authors:  Peter Fuchs; Daniel Spazierer; Gerhard Wiche
Journal:  Cell Mol Neurobiol       Date:  2005-11       Impact factor: 5.046

3.  Modeling and analysis of competitive RT-PCR.

Authors:  A L Hayward; P J Oefner; S Sabatini; D B Kainer; C A Hinojos; P A Doris
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

4.  Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue.

Authors:  F A Vlems; J H S Diepstra; I M H A Cornelissen; T J M Ruers; M J L Ligtenberg; C J A Punt; J H J M van Krieken; Th Wobbes; G N P van Muijen
Journal:  Mol Pathol       Date:  2002-06

5.  Prediction of unidentified human genes on the basis of sequence similarity to novel cDNAs from cynomolgus monkey brain.

Authors:  Naoki Osada; Munetomo Hida; Jun Kusuda; Reiko Tanuma; Makoto Hirata; Momoki Hirai; Keiji Terao; Yutaka Suzuki; Sumio Sugano; Katsuyuki Hashimoto
Journal:  Genome Biol       Date:  2001-12-19       Impact factor: 13.583

6.  Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay.

Authors:  Suzy E Meijer; Olga Klebanov-Akopyn; Vera Pavlov; Shachar Laks; David Hazzan; Aviram Nissan; Douglas Zippel
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-11-16

7.  Influence of late treatment on how chronic myeloid leukemia responds to imatinib.

Authors:  Ana Carolina Costa Scerni; Leonardo Azevedo Alvares; Ana Cristina Beltrão; Iê Regina Bentes; Tereza Cristina Azevedo; Alessandra Quinto Bentes; José Alexandre Rodrigues Lemos
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.